MYC promotes the development of papillary thyroid carcinoma by inhibiting the expression of lncRNA PAX8‑AS1:28

Zhang,Yi; Li,Feilei; Chen,Jun

doi:10.3892/or.2019.6996

MYC promotes the development of papillary thyroid carcinoma by inhibiting the expression of lncRNA PAX8‑AS1:28

Authors:
- Yi Zhang
- Feilei Li
- Jun Chen
View Affiliations

Affiliations: Department of Neck Surgery, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China, Department of Immunology, Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
Published online on: February 1, 2019 https://doi.org/10.3892/or.2019.6996
Pages: 2511-2517

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As a common malignancy of the endocrine system, papillary thyroid carcinoma (PTC) seriously affects the quality of life of patients. lncRNA PAX8‑AS1:28, or lnc‑PSD4‑1:14 has been reported to be abnormally expressed in PTC. However, the function of PAX8‑AS1:28 in PTC is still unknown. Therefore, the present study aimed to investigate the functions of PAX8‑AS1:28 in PTC, and to explore the possible mechanisms of action. A total of 38 patients with PTC were included and the normal thyroid follicular epithelial cell line Nthy‑ori 3‑1 and PTC cell line IHH‑4 were also used. MYC and PAX8‑AS1:28 overexpression and siRNA silencing in the cell lines were carried out. Expression of PAX8‑AS1:28, PAX8 and MYC in tumor tissue, adjacent healthy tissue and different cell lines were detected by qRT‑PCR and western blot analysis. Cell proliferation was measured by CCK‑8 assay. Expression levels of PAX8‑AS1:28 and PAX8 were lower in PTC tumor tissue and PTC cells than those in healthy tissue and normal cells. In contrast, the expression level of MYC was higher in PTC cells than that in normal cells. PAX8‑AS1:28 silencing reduced the expression level of PAX8 and promoted tumor cell growth, while PAX8‑AS1:28 overexpression increased the expression level of PAX8 and inhibited tumor cell growth. MYC silencing increased expression levels of PAX8‑AS1:28 and PAX8 and inhibited tumor cell growth, while MYC overexpression decreased expression levels of PAX8‑AS1:28 and PAX8 and promoted tumor cell growth. MYC can promote PTC by inhibiting the expression of lncRNA PAX8‑AS1:28.

View Figures

View References

1	Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL, Auman JT, Balasundaram M, Balu S, Baylin SB, et al: Integrated genomic characterization of papillary thyroid carcinoma. Cell. 159:676–690. 2014. View Article : Google Scholar : PubMed/NCBI
2	Olaleye O, Ekrikpo U, Moorthy R, Lyne O, Wiseberg J, Black M and Mitchell D: Increasing incidence of differentiated thyroid cancer in South East England: 1987–2006. Eur Arch Otorhinolaryngol. 268:899–906. 2011. View Article : Google Scholar : PubMed/NCBI
3	Londero SC, Krogdahl A, Bastholt L, Overgaard J, Trolle W, Pedersen HB, Bentzen J, Schytte S, Christiansen P and Godballe C: Papillary thyroid microcarcinoma in Denmark 1996–2008: A national study of epidemiology and clinical significance. Thyroid. 23:1159–1164. 2013. View Article : Google Scholar : PubMed/NCBI
4	Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, et al: Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 26:879–885. 2002. View Article : Google Scholar : PubMed/NCBI
5	Ito Y, Miyauchi A, Kudo T, Kihara M, Fukushima M and Miya A: The effectiveness of prophylactic modified neck dissection for reducing the development of lymph node recurrence of papillary thyroid carcinoma. World J Surg. 41:2283–2289. 2017. View Article : Google Scholar : PubMed/NCBI
6	Perkel JM: Visiting ‘Noncodarnia’. Biotechniques. 54:303–304. 2013. View Article : Google Scholar
7	Esteller M: Non-coding RNAs in human disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI
8	Wang K, Liu F, Zhou LY, Long B, Yuan SM, Wang Y, Liu CY, Sun T, Zhang XJ and Li PF: The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res. 114:1377–1388. 2014. View Article : Google Scholar : PubMed/NCBI
9	Takahashi K, Yan I, Haga H and Patel T: Long noncoding RNA in liver diseases. Hepatology. 60:744–753. 2014. View Article : Google Scholar : PubMed/NCBI
10	Prensner JR and Chinnaiyan AM: The emergence of lncRNAs in cancer biology. Cancer Discov. 1:391–407. 2011. View Article : Google Scholar : PubMed/NCBI
11	Lan X, Zhang H, Wang Z, Dong W, Sun W, Shao L, Zhang T and Zhang D: Genome-wide analysis of long noncoding RNA expression profile in papillary thyroid carcinoma. Gene. 569:109–117. 2015. View Article : Google Scholar : PubMed/NCBI
12	Xing M: Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199. 2013. View Article : Google Scholar : PubMed/NCBI
13	Zerilli M, Zito G, Martorana A, Pitrone M, Cabibi D, Cappello F, Giordano C and Rodolico V: BRAF^V600E mutation influences hypoxia-inducible factor-1α expression levels in papillary thyroid cancer. Mod Pathol. 23:1052–1060. 2010. View Article : Google Scholar : PubMed/NCBI
14	Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC and Franklyn JA: Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab. 91:4295–4301. 2006. View Article : Google Scholar : PubMed/NCBI
15	Clevers H and Nusse R: Wnt/β-catenin signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
16	Xiang C, Zhang ML, Zhao QZ, Xie QP, Yan HC, Yu X, Wang P and Wang Y: LncRNA-SLC6A9-5:2: A potent sensitizer in ¹³¹I-resistant papillary thyroid carcinoma with PARP-1 induction. Oncotarget. 8:22954–22967. 2017. View Article : Google Scholar : PubMed/NCBI
17	Wang X, Lu X, Geng Z, Yang G and Shi Y: LncRNA PTCSC3/miR-574-5p governs cell proliferation and migration of papillary thyroid carcinoma via Wnt/β-catenin signaling. J Cell Biochem. 118:4745–4752. 2017. View Article : Google Scholar : PubMed/NCBI
18	Yu V, Singh P, Rahimy E, Zheng H, Kuo SZ, Kim E, Wang-Rodriguez J and Ongkeko WM: RNA-seq analysis identifies key long non-coding RNAs connected to the pathogenesis of alcohol-associated head and neck squamous cell carcinoma. Oncol Lett. 12:2846–2853. 2016. View Article : Google Scholar : PubMed/NCBI
19	Luo YH, Liang L, He RQ, Wen DY, Deng GF, Yang H, He Y, Ma W, Cai XY, Chen JQ, et al: RNA-sequencing investigation identifies an effective risk score generated by three novel lncRNAs for the survival of papillary thyroid cancer patients. Oncotarget. 8:74139–74158. 2017.PubMed/NCBI
20	Plachov D, Chowdhury K, Walther C, Simon D, Guenet JL and Gruss P: Pax8, a murine paired box gene expressed in the developing excretory system and thyroid gland. Development. 110:643–651. 1990.PubMed/NCBI
21	Wolfer A and Ramaswamy S: MYC and metastasis. Cancer Res. 71:2034–2037. 2011. View Article : Google Scholar : PubMed/NCBI
22	Hu YJ, Luo XY, Yang Y, Chen CY, Zhang ZY and Guo X: Characterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma. Genet Mol Res. 14:15325–15330. 2015. View Article : Google Scholar : PubMed/NCBI
23	Zhu X, Zhao L, Park JW, Willingham MC and Cheng SY: Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation. Neoplasia. 16:757–769. 2014. View Article : Google Scholar : PubMed/NCBI
24	Van der Wal E, Bergsma AJ, Pijnenburg JM, Van der Ploeg AT and Pijnappel WWMP: Antisense oligonucleotides promote exon inclusion and correct the common c.-32-13T>G GAA splicing variant in pompe disease. Mol Ther Nucleic Acids. 7:90–100. 2017. View Article : Google Scholar : PubMed/NCBI